NSE · BLUEJET
Blue Jet Healthcare Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹9,47,32,10,000 Cr with net profit ₹2,47,81,60,000 Cr — a 26.16% net margin, versus 29.63% the period before.
Shareholding
As of 2026-06-30
- Promoter73.15%
- Public17.11%
- FII0.62%
- DII9.12%
78,927 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.54× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 6.67 percentage points to 73.15% in the latest disclosure.
Peer comparison
Biotechnology · ranked #1 of 1 by market cap
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Blue Jet Healthcare Ltd.(this company) | — | 162.47 | 7.69 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashBlue Jet Healthcare Limited, incorporated in 1968 and headquartered in Thane, India, manufactures and sells pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company provides contrast media intermediates, niche pharmaceutical intermediates and APIs, and CDMO/CMO services. It develops, manufactures, and markets saccharin and related salts, operating in India, Norway, France, the United States, Italy, Sweden, and internationally.
Positives
- +The company maintains a high promoter holding of 73.145% as of June 30, 2026.
- +The debt-to-equity ratio is low at 0.24, indicating a manageable debt load.
- +The profit margin is 26.16%, demonstrating operational efficiency.
- +Return on Capital Employed (ROCE) is 24.16%, suggesting efficient use of capital.
Negatives
- −Revenue growth for the latest period was negative at -7.3%.
- −FII shareholding decreased from 2.024% in June 2024 to 0.6245% by June 2026.
- −Quarterly revenue saw a decline from Rs 354.76 Cr in Jun 2025 to Rs 234.67 Cr in Mar 2026.
- −Quarterly net profit decreased from Rs 91.17 Cr in Jun 2025 to Rs 64.34 Cr in Mar 2026.
Business Overview
Blue Jet Healthcare Ltd. engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These products are used in pharmaceutical and healthcare applications. The company also offers CDMO/CMO services and end-to-end solutions for process development and commercialization of NCEs, advanced intermediates, APIs, and building blocks. Additionally, it develops, manufactures, and markets saccharin and related salts. The company maintains an international presence with operations in multiple countries including India, Norway, France, the United States, Italy, and Sweden.
Financial Performance
For the most recent financial year, Blue Jet Healthcare Ltd. reported revenue of Rs 947.32 Cr. This represents a revenue growth of -7.3%. The company's net profit for the same period was Rs 247.81 Cr. Profit margin for the company stands at 26.16%. The diluted EPS for the latest period is Rs 13.09.
Profitability & Returns
Blue Jet Healthcare Ltd. achieved a return on equity (ROE) of 18.22%. The return on capital employed (ROCE) is 24.16%. The company's profit margin is 26.16%. The latest reported Earnings Per Share (EPS) is Rs 13.09, which translates to a Price-to-Earnings (PE) ratio of 44.72.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.24, indicating its reliance on debt financing. The book value per share is Rs 114.11. Market capitalization stands at Rs 11080 Cr.
Ownership & Pledges
Public shareholding is 17.1095%. There are no promoter shares pledged as of the latest disclosure.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.